4.7 Article

Outcomes of Localized Prostate Cancer Following Conservative Management

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 302, 期 11, 页码 1202-1209

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.1348

关键词

-

资金

  1. US Army Medical Research Acquisition Activity, Fort Detrick, MD [DAMD17-01-10755]
  2. Department of Defense award [W81XWG-05-1-0235]
  3. Ohl Foundation [R01 CA116399]
  4. National Cancer Institute [CA-72720-10]

向作者/读者索取更多资源

Context Most newly diagnosed prostate cancers are clinically localized, and major treatment options include surgery, radiation, or conservative management. Although conservative management can be a reasonable choice, there is little contemporary prostate-specific antigen (PSA)-era data on outcomes with this approach. Objective To evaluate the outcomes of clinically localized prostate cancer managed without initial attempted curative therapy in the PSA era. Design, Setting, and Participants A population-based cohort study of men aged 65 years or older when they were diagnosed (1992-2002) with stage T1 or T2 prostate cancer and whose cases were managed without surgery or radiation for 6 months after diagnosis. Living in areas covered by the Surveillance, Epidemiology, and End Results (SEER) program, the men were followed up for a median of 8.3 years (through December 31, 2007). Competing risk analyses were performed to assess outcomes. Main Outcome Measures Ten-year overall survival, cancer-specific survival, and major cancer related interventions. Results Among men who were a median age of 78 years at cancer diagnosis, 10-year prostate cancer-specific mortality was 8.3%(95% confidence interval [CI], 4.2%-12.8%) formen with well-differentiated tumors; 9.1%(95% CI, 8.3%-10.1%) for those with moderately differentiated tumors, and 25.6% (95% CI, 23.7%-28.3%) for those with poorly differentiated tumors. The corresponding 10-year risks of dying of competing causes were 59.8%(95% CI, 53.2%-67.8%), 57.2%(95% CI, 52.6%-63.9%), and 56.5%(95% CI, 53.6%-58.8%), respectively. Ten-year disease-specific mortality for men aged 66 to 74 years diagnosed with moderately differentiated disease was 60% to 74% lower than earlier studies: 6%(95% CI, 4%-8%) in the contemporary PSA era (1992-2002) compared with results of previous studies(15%-23%) in earlier eras (1949-1992). Improved survival was also observed in poorly differentiated disease. The use of chemotherapy (1.6%) or major interventions for spinal cord compression (0.9%) was uncommon. Conclusions Results following conservative management of clinically localized prostate cancer diagnosed from 1992 through 2002 are better than outcomes among patients diagnosed in the 1970s and 1980s. This may be due, in part, to additional lead time, overdiagnosis related to PSA testing, grade migration, or advances in medical care. JAMA. 2009; 302(11): 1202-1209

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据